

Question from the clinic: The Glucagon-like-peptide-1 Receptor Agonists (GLP1-RA) are getting confusing with all of the different names, indications, and dosing. Can you please give me a tool to simplify this?

Generic Names	Brand Names	Dosing Range	Dosing Interval	Indications*				
				TYPE 2 DM	ASCVD:	OBESITY/ OVERWEIGHT	CKD	OSA
Dulaglutide	TRULICITY	0.75 – 4.5 mg	SQ WEEKLY	YES > 10 years old	YES w/T2DM			
Liraglutide	VICTOZA	0.6 – 3 mg	SQ DAILY	YES > 10 years old	YES w/T2DM			
	SAXENDA	0.6 – 3 mg	SQ DAILY	--	---	YES > 12 years old		
Semaglutide	OZEMPIC	0.25 – 2 mg	SQ WEEKLY	YES	YES w/T2DM		YES Adults w/T2DM	
	WEGOVY	0.25 – 2.4 mg	SQ WEEKLY	--	YES Adults w/Obesity	YES > 12 years old		
	RYBELSUS	3 - 14 mg PO	ORAL DAILY	YES				
Tirzepatide (GLP1/GIP RA)	MOUNJARO	2.5 – 15 mg	SQ WEEKLY	YES				
	ZEPBOUND	2.5 – 15 mg	SQ WEEKLY	--		YES Adults only		YES- Adults

***INDICATIONS EXPANDED:**

- **Type 2 DM:** An adjunct with diet and exercise to improve glycemic control in persons with Type 2 diabetes mellitus
- **ASCVD:** Reduction of the risk of major cardiovascular events (MACE) such as death, heart attack, or stroke in ADULTS who have heart disease or multiple cardiovascular risk factors
- **OBESITY/OVERWEIGHT:**
 - An adjunct to a reduced-calorie diet and increased physical activity for reduction of excess body weight and to maintain weight reduction long term in ADULTS with:
 - Obesity (BMI > 30 kg/m²)
 - Overweight (BMI > 27 kg/m²) in the presence of at least one weight-related comorbid condition (e.g. hypertension, type 2 diabetes mellitus, or dyslipidemia)
 - In pediatric persons > 12 years old (Saxenda/Wegovy)
 - Body weight > 60 kg AND an initial BMI corresponding to 30 kg/m² for adults by international cut-offs
- **CKD:** Reduction of the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease
- **OSA:** Treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity
- **MASH:** Watch for this...

What about Exenatide? (Byetta and Bydureon BCise):

- Byetta and Bydureon pen production was discontinued 10/28/24.
- For more information: <https://medicalinformation.astrazeneca-us.com/> - search “press releases”

What about Lixisenatide (Adlyxin)

- The brand name was discontinued, and it is now only available in combination with insulin glargine (Soliqua).

Other GLP1-RA agents to watch:

- Retatrutide – A tri-agonist at GLP-1, GIP, and Glucagon Receptor – in Phase III
 - <https://investor.lilly.com/news-releases/news-release-details/lillys-phase-2-retatrutide-results-published-new-england-journal> \
 - <https://trials.lilly.com/en-US/trial/405675>
- Survodutide – GLP-1 and Glucagon
 - <https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/survodutide-us-fda-breakthrough-therapy-phase-3-trials-mash>
- Orforglipron – ORAL GLP1-RA
 - <https://pmc.ncbi.nlm.nih.gov/articles/PMC10896246/>
 - <https://trials.lilly.com/en-US/trial/397395>
- Danuglipron – ORAL GLP1-RA
 - <https://www.pfizer.com/news/press-release/press-release-detail/pfizer-advances-development-once-daily-formulation-oral-glp>

Sources:

- <https://www.novo-pi.com/ozempic.pdf>
- <https://www.novo-pi.com/wegovy.pdf>
- <https://uspl.lilly.com/trulicity/trulicity.html#pi>
- <https://www.novo-pi.com/victoza.pdf>
- <https://www.novo-pi.com/saxenda.pdf>
- <https://www.novo-pi.com/rybelsus.pdf>
- <https://uspl.lilly.com/mounjaro/mounjaro.html#pi>
- <https://uspl.lilly.com/zepbound/zepbound.html#pi>